Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31658274 | 1.00 | TRPV4 (0.50) | TRPV4PRKDCTSHRLCKFYN | |
| SCHEMBL29679428 | 0.90 | TRPV4 (0.49) | TRPV4PRKDCTSHRPKMPOLB | |
| SCHEMBL5745043 | 0.90 | TRPV4 (0.49) | TRPV4PRKDCTSHRPKMPOLB | |
| SCHEMBL31036241 | 0.87 | GAA (0.51) | TRPV4TSHRPKMPOLBALDH1A1 | |
| SCHEMBL5240836 | 0.87 | TRPV4 (0.50) | TRPV4PRKDCTSHRPOLBALDH1A1 | |
| SCHEMBL25381430 | 0.85 | TRPV4 (0.45) | TRPV4PRKDCTSHRPKMALDH1A1 | |
| SCHEMBL7450372 | 0.83 | LCK (0.57) | TRPV4PRKDCTSHRLCKFYN | |
| SCHEMBL6819016 | 0.82 | PKM (0.58) | PRKDCTSHRLCKFYNPKM | |
| SCHEMBL6819356 | 0.81 | TRPV4 (0.41) | TRPV4PRKDCTSHRPKMALDH1A1 | |
| SCHEMBL31075362 | 0.81 | TRPV4 (0.41) | TRPV4PRKDCTSHRPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585216-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF FATTY LIVER DISEASE | ScandiEdge Therapeutics AB (SE) | 2025-07-16 | — | — | EP | disclosed |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | VIVIDION THERAPEUTICS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-7026349-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1385495-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-21 | — | — | EP | disclosed |
| EP-1399137-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1385507-A4 | SULFONAMIDES | SMITHKLINE BEECHAM CORP (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-6849635-B2 | Sulfonamides | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1248607-A4 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040152906-A1 | Sulfonamides | SHELL OIL COMPANY | 2004-08-05 | — | — | US | disclosed |
| EP-1385495-A2 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| EP-1385507-A1 | SULFONAMIDES | SmithKline Beecham Corporation (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030100580-A1 | Urotensin-II receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-05-29 | — | — | US | disclosed |
| WO-2002089792-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089740-A2 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002089785-A1 | SULFONAMIDES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-11-14 | — | — | WO | disclosed |
| EP-1248607-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001045694-A1 | UROTENSIN-II RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-1998038182-A9 | HYPOLIPIDEMIC BICYCLIC DERIVATIVES | GLAXO GROUP LTD (GB) | 1999-04-15 | — | — | WO | disclosed |
| WO-1998038182-A1 | HYPOLIPIDEMIC BICYCLIC DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100580-A1 | Urotensin-II receptor antagonists | UTS2R, TMPRSS4, PLAUR | TRPV4 134/4885PRKDC 4821/4885TSHR 641/4885 |
| US-20250026721-A1 | COMPOUNDS AND METHODS FOR MODULATING RAS-PI3K | KRAS, HRAS, NRAS | TRPV4 4643/4885PRKDC 523/4885TSHR 2577/4885 |
| US-20050043536-A1 | antagonists of urotensin II; for example, 2,6-Dichloro-N-[3-(dimethylamino-ethoxy)4-trifluoromethyl-phenyl]-4trifluoromethyl-benzenesulfonamide | UTS2R, SPINT2, PRSS2 | TRPV4 664/4885PRKDC 4733/4885TSHR 1427/4885 |
| US-20040152906-A1 | Sulfonamides | UTS2R, PRSS2, STS | TRPV4 1003/4885PRKDC 4848/4885TSHR 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.